Daohua Jiang

2 months ago | febs.onlinelibrary.wiley.com | Di Wu |Yan Zhao |Daohua Jiang

Conflicts of interest The authors declare no conflict of interest. References 1, & (1995) Vesicular neurotransmitter transporters: from bacteria to humans. Physiol Rev 75, 369–392. 2, , & (2015) Monoamine neurotransmitter disorders: clinical advances and future perspectives. Nat Rev Neurol 11, 567–584. 3, & (1981) Proton: substrate stoichiometries during active transport of biogenic amines in chromaffin ghosts. J Biol Chem 256, 5773–5780.

Jan 13, 2025 | nature.com | Kunpeng Ma |Yanli Dong |Jun Zhao |Di Wu |Daohua Jiang

AbstractThe vesicular acetylcholine transporter (VAChT) has a pivotal role in packaging and transporting acetylcholine for exocytotic release, serving as a vital component of cholinergic neurotransmission. Dysregulation of its function can result in neurological disorders. It also serves as a target for developing radiotracers to quantify cholinergic neuron deficits in neurodegenerative conditions.

May 21, 2024 | nature.com | Di Wu |Jun Zhao |Daohua Jiang

Dear Editor,Monoamine neurotransmitters include indolamine serotonin (5-HT), the catecholamine dopamine (DA), epinephrine (EP), norepinephrine (NE), and imidazolamine histamine (HA).1 These neurotransmitters are critical in emotion, arousal, mood, reward, sleep, and memory.2 VMAT2 accumulates monoamine neurotransmitters into synaptic vesicles for storage and eventual exocytotic release.